Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Trevena Inc.
Hot on the heels of an oversubscribed series B round, OMass CEO and Rising Leader Ros Deegan spoke with In Vivo about her move from pharma to biotech, mass spectrometry and big dreams for the firm.
Public Company Edition: Only nine drug developers went public in the US, raising $807m in the first quarter, versus 32 IPOs raising $5.2bn in Q1 of last year. Also, MoonLake closed its SPAC merger, Sanofi priced €650m in sustainability-linked bonds in €1.5bn note sale, and Kaleido will cease operations.
With 46 initial public offerings in the US by drug developers so far – including recent launches by Kymera, Inhibrx and Harmony – 2020 will easily beat last year’s 50 IPOs. In follow-on offerings and VC deals, newly public Schrodinger raised $346.5m and Tango’s $50m equity financing.
Keeping Track: Veklury NDA Arrives At US FDA; Olinvyk Sees Approval; MAb Filings By Regneron, Y-mAbs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Drug Discovery Tools
- Large Molecule